Inclusion Criteria:

- Age ≥ 18 years or minimum age of consent per local regulations at the time of
screening

- Unresectable or metastatic hepatocellular carcinoma

- ECOG Performance Status ≤ 2

- Life expectancy of ≥ 3 months;

Exclusion Criteria:

- Child-Pugh Score for Cirrhosis Mortality > 7 points

- Prior or current system anti-cancer therapy for HCC, including cytotoxic, biologic,
targeted or experimental therapy

- Prior local treatment for HCC less than 4 weeks prior to initiating study treatment

- Active second malignancy

- Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to
initiating study treatment

- Thrombotic or embolic events within 6 months prior to initiating study treatment

- Ongoing pancreatitis

- Uncontrolled or refractory ascites

- Evidence of ongoing spinal cord compression, known carcinomatous meningitis, or known
leptomeningeal carcinomatosis

- Hepatic encephalopathy > Grade 1

- Active brain metastases with exceptions

- Poorly controlled diabetes mellitus

- Active coronary artery disease

- Uncontrolled hypertension